- Home
- NGEN vs CRBP Comparison
NGEN vs CRBP Comparison
Compare NGEN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGEN | CRBP |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.0M | 190.3M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NGEN | CRBP |
|---|---|---|
| Price | $2.18 | $8.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $18.00 | ★ $45.50 |
| AVG Volume (30 Days) | 605.4K | ★ 606.6K |
| Earning Date | 04-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.58 | $7.12 |
| 52 Week High | $5.93 | $20.56 |
Technical Indicators
Market Signals| Indicator | NGEN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 31.12 |
| Support Level | $1.62 | $7.62 |
| Resistance Level | $2.32 | $8.54 |
| Average True Range (ATR) | 0.16 | 0.72 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 63.60 | 2.71 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.